These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21763367)

  • 1. Recent advances and novel strategies in pre-clinical formulation development: an overview.
    Shah AK; Agnihotri SA
    J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in intravenous delivery of poorly water-soluble compounds.
    Shi Y; Porter W; Merdan T; Li LC
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling.
    Maas J; Kamm W; Hauck G
    Eur J Pharm Biopharm; 2007 Apr; 66(1):1-10. PubMed ID: 17123801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral formulation strategies to improve solubility of poorly water-soluble drugs.
    Singh A; Worku ZA; Van den Mooter G
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1361-78. PubMed ID: 21810062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical formulations for discovery and toxicology: physicochemical challenges.
    Neervannan S
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic use of preparative chiral chromatography for the synthesis of a preclinical pharmaceutical candidate.
    Leonard WR; Henderson DW; Miller RA; Spencer GA; Sudah OS; Biba M; Welch CJ
    Chirality; 2007 Sep; 19(9):693-700. PubMed ID: 17354260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical formulations: insight, strategies, and practical considerations.
    Shah SM; Jain AS; Kaushik R; Nagarsenker MS; Nerurkar MJ
    AAPS PharmSciTech; 2014 Oct; 15(5):1307-23. PubMed ID: 24920522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metal complexes in medicinal chemistry: new vistas and challenges in drug design.
    Thompson KH; Orvig C
    Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
    Pouton CW; Porter CJ
    Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.